500257 Stock Overview
Lupin Limited, a pharmaceutical company, develops, produces, markets, and sells a range of branded and generic formulations, biotechnology products, and active pharmaceutical ingredients (APIs) in India and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 3/6 |
| Financial Health | 6/6 |
| Dividends | 2/6 |
Rewards
Risk Analysis
No risks detected for 500257 from our risk checks.
Lupin Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹1,547.05 |
| 52 Week High | ₹1,703.80 |
| 52 Week Low | ₹680.35 |
| Beta | 0.65 |
| 1 Month Change | -0.99% |
| 3 Month Change | 9.72% |
| 1 Year Change | 122.65% |
| 3 Year Change | 43.38% |
| 5 Year Change | 78.17% |
| Change since IPO | 51,901.68% |
Recent News & Updates
Recent updates
Shareholder Returns
| 500257 | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | -4.7% | -2.5% | -2.5% |
| 1Y | 122.6% | 55.2% | 44.5% |
Return vs Industry: 500257 exceeded the Indian Pharmaceuticals industry which returned 55.2% over the past year.
Return vs Market: 500257 exceeded the Indian Market which returned 44.5% over the past year.
Price Volatility
| 500257 volatility | |
|---|---|
| 500257 Average Weekly Movement | 3.0% |
| Pharmaceuticals Industry Average Movement | 6.0% |
| Market Average Movement | 6.9% |
| 10% most volatile stocks in IN Market | 10.1% |
| 10% least volatile stocks in IN Market | 4.3% |
Stable Share Price: 500257 has not had significant price volatility in the past 3 months.
Volatility Over Time: 500257's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1968 | 20,933 | Vinita Gupta | www.lupin.com |
Lupin Limited, a pharmaceutical company, develops, produces, markets, and sells a range of branded and generic formulations, biotechnology products, and active pharmaceutical ingredients (APIs) in India and internationally. It offers formulations for use in the therapeutic areas of cardiovascular, diabetology, asthma, pediatrics, central nervous system, gastrointestinal, anti-infective, nonsteroidal anti-inflammatory drug therapy, respiratory, women’s health, and anti-tuberculosis. The company is also involved in the provision of biosimilars; over-the-counter products; specialty products; and drug discovery and development programs in the therapeutic areas of oncology, immunology, and metabolic disorders, as well as bio clinical research activities.
Lupin Limited Fundamentals Summary
| 500257 fundamental statistics | |
|---|---|
| Market cap | ₹726.31b |
| Earnings (TTM) | ₹17.91b |
| Revenue (TTM) | ₹194.80b |
39.4x
P/E Ratio3.6x
P/S RatioIs 500257 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 500257 income statement (TTM) | |
|---|---|
| Revenue | ₹194.80b |
| Cost of Revenue | ₹72.72b |
| Gross Profit | ₹122.08b |
| Other Expenses | ₹104.17b |
| Earnings | ₹17.91b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 39.30 |
| Gross Margin | 62.67% |
| Net Profit Margin | 9.19% |
| Debt/Equity Ratio | 28.4% |
How did 500257 perform over the long term?
See historical performance and comparison